Javier Rodriguez Sells 50,000 Shares of DaVita Inc. (NYSE:DVA) Stock

DaVita Inc. (NYSE:DVA) CEO Javier Rodriguez sold 50,000 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the sale, the chief executive officer now directly owns 837,835 shares in the company, valued at $138,284,666.75. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Javier Rodriguez also recently made the following trade(s):

• On Friday, September 13th, Javier Rodriguez sold 9,881 shares of DaVita stock. The stock was sold at an average price of $162.85, for a total value of $1,609,120.85.
• On Monday, August 26th, Javier Rodriguez sold 32,176 shares of DaVita stock. The stock was sold at an average price of $155.93, for a total value of $5,017,203.68.

DaVita Price Performance

DaVita stock opened at $163.16 on Thursday. DaVita Inc. has a 12 month low of $71.51 and a 12 month high of $166.04. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94. The company has a market capitalization of $14.31 billion, a PE ratio of 18.54, a P/E/G ratio of 0.95 and a beta of 0.87. The stock has a 50-day moving average price of $146.25 and a two-hundred day moving average price of $140.54.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.47 by $0.12. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The company had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.15 billion. During the same period last year, the company earned $2.08 earnings per share. The firm’s revenue was up 6.2% compared to the same quarter last year. Analysts expect that DaVita Inc. will post 9.99 EPS for the current year.

Hedge Funds Weigh In On DaVita

A number of hedge funds have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. raised its position in shares of DaVita by 60.2% during the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,498 shares of the company’s stock worth $208,000 after acquiring an additional 563 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in DaVita during the second quarter worth approximately $9,615,000. Chase Investment Counsel Corp acquired a new stake in DaVita during the second quarter worth approximately $2,933,000. B. Riley Wealth Advisors Inc. grew its stake in DaVita by 78.9% during the second quarter. B. Riley Wealth Advisors Inc. now owns 4,130 shares of the company’s stock worth $572,000 after purchasing an additional 1,822 shares during the period. Finally, Creative Planning grew its stake in DaVita by 5.0% during the second quarter. Creative Planning now owns 8,297 shares of the company’s stock worth $1,150,000 after purchasing an additional 394 shares during the period. 90.12% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on DVA shares. UBS Group upped their price objective on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. TD Cowen upped their price objective on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 8th. Truist Financial increased their target price on DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a research report on Tuesday, August 20th. Finally, Bank of America increased their target price on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $157.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.